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Moderate to severe chronic kidney disease (CKD), mainly expressed by estimated glomerular filtration rate 
(eGFR) <60 mL/min per 1.73 m2, is strongly associated with 
increased mortality among patients with heart failure, whereas 
these findings are far less established in the presence of mild 
impaired renal function.1,2
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Interestingly, serum creatinine is relatively insensitive to 
changes in the GFR, and kidney disease is not only reflected 
by GFR. In patients with intrinsic kidney failure, tubuloint-
erstitial damage is an established marker for renal disease as 
well.3 In different pathogenesis of kidney failure, tubuloint-
erstitial hypoxia seems to be an early marker for the develop-
ment of kidney failure.4–13 Several studies showed that tubular 
markers are increased before an increase of creatinine is 
observed.14–17
We recently demonstrated that urinary markers of tubular 
damage, such as N-acetyl-β-D-glucosaminidase, kidney injury 
molecule 1, and neutrophil gelatinase–associated lipocalin 
(NGAL), were elevated in patients with heart failure.3,18 In addi-
tion, the tubular markers, urinary N-acetyl-β-d-glucosaminidase 
and kidney injury molecule 1, were related to a poor progno-
sis, independent of eGFR.19 Also, in a much larger sub-study 
of the GISSI-HF  (The Gruppo Italiano per lo Studio della 
Sopravvivenza nell'Infarto Miocardico-Heart Failure Study) 
trial, urinary NGAL levels were independently associated with 
cardiovascular outcome.19 Few studies in patients with heart 
failure have indicated that higher plasma markers of tubular 
damage are also related to an increased risk of mortality.20–24
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Background—In patients with heart failure, renal dysfunction is associated with a poor outcome. We aimed to assess the 
prognostic value of plasma neutrophil gelatinase–associated lipocalin (NGAL), a novel marker of renal tubular damage, 
in patients with heart failure with or without renal dysfunction, and compare it with 2 frequently used biomarkers of 
chronic kidney disease.
Methods and Results—Plasma NGAL, estimated glomerular filtration rate (eGFR), and cystatin C were assessed in 
562 patients with heart failure. Chronic kidney disease was defined as eGFR<60 mL/min per 1.73 m2. Outcome 
was all-cause mortality at 36 months. Mean age was 71±11 years, 61% were men, and 97% were in New York 
Heart Association functional class II/III. Mean baseline eGFR was 54±20 mL/min per 1.73 m2, mean cystatin C 
was 11.2 (7.7–16.2) mg/L, and median plasma NGAL was 85 (60–123) ng/mL. Higher plasma NGAL levels were 
independently associated with an increased risk of all-cause mortality, in patients with and without chronic kidney 
disease (hazard ratio [per SD increase in log NGAL]=1.45 [1.22–1.72]; P<0.001 and hazard ratio=1.51 [1.06–2.16]; 
P=0.023, respectively). Similarly, both in patients with high and low cystatin C (median cut-off), higher plasma 
NGAL levels were independently associated with an increased risk of all-cause mortality. Moreover, when NGAL 
was entered in the multivariable risk prediction model, eGFR (P=0.616) and cystatin C (P=0.937) were no longer 
associated with mortality.
Conclusions—Plasma NGAL predicts mortality in patients with heart failure, both in patients with and without 
chronic kidney disease and is a stronger predictor for mortality than the established renal function indices eGFR and 
cystatin C.  (Circ Heart Fail. 2014;7:35-42.)
Key Words: heart failure ◼ NGAL protein, human ◼ prognosis
Received February 1, 2013; accepted December 9, 2013.
From the Department of Cardiology (V.M.v.D., K.D., A.A.V., M.H.v.d.W., D.J.v.V., H.L.H.) and Department of Epidemiology (H.L.H.), University 
Medical Center Groningen, University of Groningen, Groningen, The Netherlands; and Department of Social and Welfare Studies, Faculty of Health 
Sciences, Linköping University, Norrköping, Sweden (T.J.).
The Data Supplement is available at  http://circheartfailure.ahajournals.org/lookup/suppl/doi:10.1161/CIRCHEARTFAILURE.113.000242/-/DC1. 
Correspondence to Adriaan A. Voors, MD, PhD, Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 
9700 RB Groningen, The Netherlands. E-mail a.a.voors@umcg.nl
Prognostic Value of Plasma Neutrophil  
Gelatinase–Associated Lipocalin for Mortality  
in Patients With Heart Failure
Vincent M. van Deursen, MD, PhD; Kevin Damman, MD, PhD; Adriaan A. Voors, MD, PhD;  
Martje H. van der Wal, PhD; Tiny Jaarsma, PhD; Dirk J. van Veldhuisen, MD, PhD;  
Hans L. Hillege, MD, PhD
 by guest on September 24, 2016http://circheartfailure.ahajournals.org/Downloaded from 
36  Circ Heart Fail  January 2014
However, the prognostic value of plasma tubular damage 
in patients with normal or mildly impaired renal function has 
been less well described.23 The aims of this study were first to 
assess the role and performance of the tubular marker plasma 
NGAL as a prognostic marker of mortality in patients with 
heart failure with both normal and impaired renal function. 
Second, we aimed to compare the prognostic value of plasma 
NGAL with 2 frequently used biomarkers of CKD.
Methods
Patient Population
This is a retrospective analysis of the Coordinating study evaluating 
Outcomes of Advising and Counseling in Heart failure (COACH), a 
multicenter, randomized, open trial, designed to compare usual care, 
basic support, and intensive support in patients with heart failure, 
conducted between 2002 and 2007 in The Netherlands.25,26 Patients 
were included just before discharge of their hospitalization for acute 
decompensated heart failure. The study was conducted in accordance 
with the guidelines of the Declaration of Helsinki and approved by 
the locally appointed ethics committees. All patients provided written 
informed consent for the main study. Of all 1023 patients from the 
COACH, 562 patients had baseline plasma available for this analysis. 
Demographic and clinical data were collected from chart review.
Renal Function
We calculated eGFR (mL/min per 1.73 m2) using the simplified mod-
ification of diet in renal disease formula (186.3×(serum creatinine 
[mg/dL])–1.154×age–0.203×[0.742 if women])27 at discharge and after 6 
months. Cystatin C was measured using a Luminex assay by Alere 
San Diego (R&D). Plasma NGAL was measured using a simulta-
neous ELISA developed in-house at Alere San Diego. The primary 
antibody was biotinylated and bound to a neutravidin plate. The 
secondary antibody was labeled with fluorescein, which serves as a 
hapten for an antifluoroscein antibody labeled with alkaline phospha-
tase. All other liquid handling steps were performed with a Beckman 
Biomek FX. Intra-/interassay variability were 15.8%/15.7% for 27 
ng/mL, 13.5%/13.7% for 280 ng/mL, and 17.1%/17.1% for 860 ng/
mL, respectively. The analysis was performed independent of the data 
analysis.
Other Biomarkers
To account for the possible inflammatory association of NGAL, 
C-reactive protein was measured using a bead-based immunoassay 
performed in microtiter plates. The primary antibody was conju-
gated to modified paramagnetic Luminex beads obtained from Radix 
Biosolutions; purified C-reactive protein was biotinylated.
B-type natriuretic peptide (BNP) was measured using a 
 bead-based immunoassay performed in microtiter plates. The pri-
mary antibody was conjugated to modified paramagnetic Luminex 
beads obtained from Radix Biosolutions; the secondary anti-
body was biotinylated. Fluorescent signals were generated using 
 Streptavidin-R-Phycoerythrin (SA-RPE: Prozyme PJ31S).
Outcome
The extended outcome of the COACH trial consisted of mortality as-
sessed at 36 months, for which additional ethical committee approval 
was obtained.
Statistical Analyses
Patients were divided into 2 groups according to the value of eGFR: 
the CKD group (eGFR<60 mL/min per 1.73 m2 by modification of 
diet in renal disease equation) and the non-CKD group (eGFR≥60 
mL/min per 1.73 m2). Because previous research suggests a differ-
ence in risk curves for CKD and non-CKD heart failure patients, the 
analyses were conducted separately by the presence of CKD.2 Data 
are presented as mean±SD when normally distributed, as median and 
interquartile range when non-normally distributed, and as frequen-
cies and percentages for categorical variables. Differences between 
baseline variables were evaluated by Student t test, Kruskal–Wallis 
test, Mann–Whitney U or χ2 tests where appropriate. For the Kaplan–
Meier curves, CKD classification and medians of plasma NGAL and 
cystatin C were used as cut-off points.
Cox proportional hazard analysis was used to assess whether plas-
ma NGAL is a predictor of prognosis. NGAL showed a log-linear 
functional shape with the response variable and was transformed to a 
log scale. In consecutive models, plasma NGAL was adjusted for age 
and sex, eGFR and finally for the final model, consisting of diastolic 
blood pressure, pulse pressure, history of stroke, myocardial infarc-
tion, atrial fibrillation, peripheral arterial disease, diabetes mellitus, 
left ventricular ejection fraction, previous hospitalization, serum so-
dium, BNP, and treatment (fully adjusted model).28 For confirmatory 
analysis, BNP was replaced with N-terminal pro-BNP. Interactions 
between plasma NGAL and both eGFR and cystatin C were tested. 
To evaluate predictive use of plasma NGAL, eGFR and cystatin C, 
Harrell’s C-statistics and corresponding 95% confidence interval (CI) 
generated by an approximate Jackknife method were calculated us-
ing the somersd package from STATA. Furthermore, we calculated 
the incremental value of plasma NGAL by means of the integrated 
discrimination index and net reclassification index for the model of 
all significant variables versus this model plus plasma NGAL. Cut-off 
values of mortality were arbitrarily set at 10% and 30%.
A P value of <0.05 was considered statistically significant. 
Statistical analyses were performed using R Statistics (version 
2.13.2) and STATA (version 10, College Station, TX).
Results
A total of 562 patients were available for this analysis. These 
patients did not differ significantly from the 461 excluded 
patients that originally participated in COACH (Table in the 
Data Supplement). Mean age was 71±11 years, 61% were 
men, 97% were in New York Heart Association functional 
class II or III, and 53% had been hospitalized previously 
because of heart failure. Mean baseline eGFR was 54±20 
mL/min per 1.73 m2, mean cystatin C was 11.2 (7.7–16.2) 
mg/L, and median plasma NGAL was 85 (60–123) ng/mL.
Table 1 shows the baseline characteristics of the patients 
according to CKD and non-CKD. Patients with CKD were 
older, were in a higher New York Heart Association functional 
class, were less likely to receive an angiotensin-converting 
enzyme inhibitor, had higher levels of cystatin C and NGAL, 
lower levels of hemoglobin (all P<0.001), and had more 
comorbidities. C-Reactive protein did not differ between the 
CKD and non-CKD groups (P=0.093) nor was C-reactive pro-
tein correlated with plasma NGAL (r=0.073; P=0.14).
Plasma NGAL, eGFR, and Prognosis
After a follow-up of 3 years, 232 (41%) patients died. After 3 
years, mortality in patients with CKD was 49% (n=175/357) 
compared with 28% (57/205) in the non-CKD-group (hazard 
ratio, 2.09; 95% CI, 1.55–2.81; P<0.001).
Figure 1 shows the Kaplan–Meier curves for the occurrence 
of all-cause mortality. Curves are shown for 4 groups (CKD 
and non-CKD, and high and low NGAL). There was a gradual 
increase in risk with more evidence of kidney disease (CKD 
or high NGAL). NGAL above the median was associated with 
increased risk of mortality in both CKD (hazard ratio, 1.97; 
95% CI, 1.41–2.77; P<0.001) and non-CKD (hazard ratio, 
2.05; 95% CI, 1.20–3.50; P=0.008).
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Overall, higher plasma NGAL levels were independently 
associated with increased mortality. In all consecutive models 
(plasma NGAL adjusted for age and sex, adjusted for eGFR, 
and finally for the fully adjusted model with BNP), higher 
plasma NGAL levels were independently associated with an 
increased risk of all-cause mortality (hazard ratio, 1.44 per SD 
increase in log NGAL; 95% CI, 1.22–1.69; P<0.001; Table 2). 
The prognostic values (C-statistics) of plasma NGAL and 
eGFR are shown in Table 3. Integrated discrimination index 
improved significantly adding NGAL to the fully adjusted 
model (0.029; P<0.001), whereas net reclassification index 
showed a trend toward a significant improvement (0.062; 
P=0.054). When BNP was replaced with N-terminal pro-BNP, 
results remained consistent.
Divided into CKD and non-CKD, plasma NGAL levels 
remained significantly associated in the consecutive models 
with 3-year mortality, in patients with CKD and in non-
CKD patients, whereas eGFR was only univariate associ-
ated with mortality in patients with CKD. Furthermore, 
eGFR was no longer significantly associated with mortal-
ity in patients with CKD when plasma NGAL was intro-
duced in the crude, age and sex adjusted, and fully adjusted 
model (Table 2).
Plasma NGAL, Cystatin C, and Prognosis
In accordance with eGFR, we divided cystatin C into 2 groups. 
Figure 2 shows the Kaplan–Meier curves for the occurrence of 
all-cause mortality (high and low cystatin C, and high and low 
Table 1. Baseline Characteristics of Patients According to CKD and Non-CKD






Age, y 71±11 74±10 66±11 <0.001
Sex (% women) 39 42 33 0.005
LVEF, % 32±14 33±14 32±15 0.493
NYHA, % <0.001
  2 47 39 59
  3 50 57 39
  4 3 4 2
Systolic BP, mm Hg 118±21 119±22 116±20 0.067
Diastolic BP, mm Hg 69±12 68±12 70±12 0.122
Heart rate, beats per minute 74±13 74±13 75±13 0.43
Medical history, %
  Hypertension 42 49 31 <0.001
  Peripheral arterial disease 16 18 12 0.009
  Myocardial infarction 41 45 34 0.044
  Atrial fibrillation 45 49 40 0.014
  Stroke 15 18 11 0.061
  COPD 28 31 24 0.084
Laboratory
  Cystatin C, mg/L 11.2 (7.7–16.2) 12.6 (8.7–19.2) 8.8 (7–12.6) <0.001
  NGAL, ng/mL 85 (60–123) 104 (72–151) 65 (51–85) <0.001
  Creatinine, mg/dL* 1.30 (1.03–1.64) 1.56 (1.32–1.89) 0.98 (0.87–1.14) <0.001
  Hemoglobin, g/dL 13±2 12.8±1.9 13.7±2 <0.001
  BNP, pg/mL 454 (202–904) 480 (214–997) 416 (185–785) 0.078
  CRP, mg/L 2.3 (0.9–5.1) 2.3 (1–5.5) 2.3 (0.8–4.9) 0.093
Medication use, %
  ACE inhibitor 72 68 79 <0.001
  Angiotensin receptor blocker 11 12 10 0.699
  β-Blocker 67 64 71 0.207
  Diuretic 95 96 95 0.238
  Statin 39 39 38 0.576
  Calcium antagonist 14 13 15 0.645
ACE indicates angiotensin-converting enzyme; BNP, brain-type natriuretic peptide; BP, blood pressure; CKD, chronic 
kidney disease; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; eGFR, estimated glomerular 
filtration rate; LVEF, left ventricular ejection fraction; NGAL, neutrophil gelatinase–associated lipocalin; and NYHA, New 
York Heart Association functional class.
*For μmol/L multiply by 88.4.
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NGAL). Within the groups of NGAL, there was no difference 
in mortality between the 2 cystatin C groups.
Again, higher plasma NGAL levels were independently 
associated with increased mortality, in all consecutive mod-
els (adjusted for age, sex, and cystatin C, and finally for the 
fully adjusted model with cystatin C; Table 2). The prognos-
tic value of plasma NGAL including cystatin C (measured 
by C-statistic) for the total group was higher compared with 
cystatin C without NGAL (Table 3). Integrated discrimi-
nation index improved significantly adding NGAL to the 
fully adjusted model (0.027; P<0.001), whereas net reclas-
sification index did not show improvement in discrimination 
(–0.025; P=0.409). When BNP was replaced with N-terminal 
pro-BNP, results remained consistent. The discrepancy 
in significance could be explained because integrated dis-
crimination index can be seen as the continuous version if 
net reclassification index with probability differences used 
instead of categories.
Divided into high and low cystatin C groups, plasma 
NGAL levels remained significantly associated in the 
Table 2. Risk Models of the Predictive Value of Plasma NGAL, eGFR, and Cystatin C in Patients With Heart 
Failure With and Without CKD
All Patients CKD Non-CKD
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
eGFR alone (per SD increase) 1.50 [1.30–1.72] <0.001 1.54 [1.19–1.98] <0.001 1.02 [0.66–1.56] 0.938
eGFR, age and sex adj. 1.41 [1.21–1.64] <0.001 1.51 [1.17–1.96] 0.002 0.93 [0.60–1.43] 0.726
eGFR, fully adjusted 1.28 [1.10–1.49] 0.001 1.26 [0.94–1.67] 0.121 1.04 [0.62–1.77] 0.858
eGFR, fully adjusted with NGAL 1.04 [0.88–1.24] 0.616 0.87 [0.63–1.21] 0.413 1.00 [0.60–1.67] 0.993
Cyst C alone (per SD increase) 1.15 [1.02–1.30] 0.020 1.04 [0.90–1.19] 0.623 1.24 [0.96–1.62] 0.100
Cyst C, age and sex adj. 1.11 [0.98–1.26] 0.093 1.04 [0.90–1.20] 0.573 1.18 [0.91–1.55] 0.217
Cyst C, fully adjusted 1.09 [0.96–1.23] 0.208 1.07 [0.92–1.24] 0.406 1.08 [0.82–1.44] 0.572
Cyst C, fully adjusted with NGAL 0.99 [0.87–1.14] 0.937 0.98 [0.84–1.15] 0.836 1.03 [0.77–1.38] 0.844
NGAL alone (per SD increase) 1.61 [1.42–1.83] <0.001 1.48 [1.27–1.72] <0.001 1.62 [1.17–2.23] 0.003
NGAL, age and sex adj. 1.51 [1.32–1.72] <0.001 1.44 [1.23–1.68] <0.001 1.44 [1.03–2.00] 0.033
NGAL, fully adjusted 1.47 [1.27–1.69] <0.001 1.45 [1.22–1.72] <0.001 1.51 [1.06–2.16] 0.023
NGAL, fully adjusted with eGFR 1.44 [1.22–1.69] <0.001 1.51 [1.24–1.85] <0.001 1.51 [1.06–2.16] 0.024
NGAL, fully adjusted with cyst C 1.47 [1.27–1.70] <0.001 1.45 [1.22–1.74] <0.001 1.50 [1.04–2.16] 0.026
Fully adjusted model: adjusted for age, sex, diastolic blood pressure, pulse pressure, history of stroke, myocardial infarction, atrial fibrillation, 
peripheral arterial disease, diabetes mellitus, left ventricular ejection fraction, previous hospitalization, serum sodium, B-type natriuretic 
peptide, and treatment allocation. CI indicates confidence interval; CKD, chronic kidney disease; cyst C, cystatin C; eGFR, estimated glomerular 
filtration rate; HR, hazard ratio; and NGAL, neutrophil gelatinase–associated lipocalin. 
Figure 1. Three-year mortality (chronic kidney disease [CKD] and non-CKD vs low/high neutrophil gelatinase–associated lipocalin 
[NGAL])-Kaplan–Meier curves showing the association between all-cause mortality and low/high estimated glomerular filtration rate 
(cut-off point, 60 mL/min per 1.73 m2) and low/high NGAL (cut-off point, 84.62 ng/mL). Hazard ratio vs no CKD/NGAL<median for 
CKD/NGAL<median, 1.65; 95% confidence interval (CI), 1.01 to 2.56; P=0.027; for no CKD/NGAL>median, 2.05; 95% CI, 1.20 to 3.49; 
P=0.009; and for CKD/NGAL>median, 3.26; 95% CI, 2.24 to 4.74; P<0.001.
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consecutive models with 3-year mortality, whereas cystatin C 
was not significantly associated with mortality in both groups. 
Furthermore, cystatin C was no longer significantly associ-
ated with mortality in patients with CKD when plasma NGAL 
was introduced in the crude, age and sex adjusted, and fully 
adjusted model (Table 2).
Discussion
This study shows that plasma NGAL predicts mortality in 
patients with heart failure, both in patients with and without 
CKD. Moreover, plasma NGAL is a stronger predictor for 
mortality than the frequently used biomarkers of impaired 
renal function eGFR and cystatin C.
Plasma NGAL and Prognosis
NGAL is a 25-kDa lipocalin-superfamily glycoprotein that is 
considered to play a role in acute kidney injury in a diverse 
range of settings.16,29 In normal circumstances, only small 
amounts can be found in plasma and urine. However, dur-
ing and after acute kidney injury, NGAL levels rise quickly 
and massively.30
In the present study, we found that plasma NGAL is inde-
pendently associated with mortality. This confirms our recent 
study in which we found that tubular damage in heart failure 
was prevalent in chronic heart failure and related to impaired 
survival, independent of GFR and albuminuria.18 In this small 
study, we were unable to establish the prognostic value of 
Table 3. C-Statistics of Models Comparing the Prognostic Value of eGFR and NGAL in Patients With Heart 
Failure With and Without CKD
All Patients CKD Non-CKD
eGFR 0.614 (0.578–0.650) 0.569 (0.525–0.613) 0.520 (0.436–0.604)
eGFR, fully adjusted 0.730 (0.698–0.762) 0.723 (0.686–0.761) 0.701 (0.632–0.770)
Cyst C 0.554 (0.517–0.591) 0.511 (0.467–0.555) 0.581 (0.505–0.657)
Cyst C, fully adjusted 0.725 (0.693–0.757) 0.721 (0.684–0.758) 0.703 (0.634–0.771)
NGAL 0.644 (0.609–0.680) 0.615 (0.573–0.657) 0.616 (0.543–0.689)
NGAL, fully adjusted 0.740 (0.708–0.772)
P=0.099 vs eGFR fam
P=0.030 vs cystatin C fam
0.739 (0.701–0.777)
P=0.027 vs eGFR fam
P=0.031 vs cystatin C fam
0.716 (0.648–0.784)
P=0.248 vs eGFR fam
P=0.290 vs cystatin C fam
NGAL, fully adjusted with eGFR 0.740 (0.708–0.772)
P=0.570 vs NGAL fam
0.740 (0.701–0.778)
P=0.379 vs NGAL fam
0.716 (0.648–0.784)
P=0.685 vs NGAL fam
NGAL, fully adjusted with cyst C 0.740 (0.708–0.772)
P=0.598 vs NGAL fam
0.740 (0.702–0.777)
P=0.401 vs NGAL fam
0.716 (0.648–0.784)
P=0.958 vs NGAL fam
Fam: adjusted for age, sex, eGFR, diastolic blood pressure, pulse pressure, history of stroke, myocardial infarction, atrial fibrillation, 
peripheral arterial disease, diabetes mellitus, left ventricular ejection fraction, previous hospitalization, serum sodium, B-type natriuretic 
peptide, and treatment allocation. CKD indicates chronic kidney disease; eGFR, estimated glomerular filtration rate; Fam, fully adjusted 
model; and NGAL, neutrophil gelatinase–associated lipocalin.
Figure 2. Three-year mortality (low/high cystatin C vs low/high neutrophil gelatinase–associated lipocalin [NGAL])-Kaplan–Meier curves 
showing the association between all-cause mortality and low/high cystatin C (cut-off point, 11.2 mg/L) and low/high NGAL (cut-off point, 
84.62 ng/mL). Hazard ratio vs cystatin C and NGAL<median for cystatin C>median/NGAL<median, 1.17; 95% CI, 0.74 to 1.85; P=0.50; 
for cystatin C<median/NGAL>median, 2.35; 95% CI, 1.59 to 3.47; P<0.001; and for cystatin C and NGAL>median, 2.53; 95% CI, 1.81 to 
3.54; P<0.001.
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urinary NGAL in chronic heart failure. However, in a much 
larger sub-study of the GISSI-HF trial, urinary NGAL levels 
were independently associated with outcome.19
Bolignano et al20 found prognostic significance of plasma 
NGAL levels in 46 patients with chronic heart failure. In 
3 confirmative smaller studies, serum NGAL, measured at 
admission for acute heart failure, predicted death only when 
NGAL was dichotomized by an optimally taken  cut-off 
point.21,22
In the CORONA (Controlled rosuvastatin multinational 
study in heart failure) study, with 1415 patients with chronic 
heart failure of ischemic pathogenesis, plasma NGAL was an 
univariate predictor of all-cause mortality, cardiovascular death, 
and hospitalization. However, plasma NGAL was no longer a 
significant predictor when adjusted for GFR and N-terminal 
pro-BNP.23 In contrast, Alvelos et al22 showed that plasma 
NGAL was an independent predictor of increased risk of short-
term death and readmission in patients with acute heart failure. 
In the recent NGAL EvaLuation Along with B-type NaTriuretic 
Peptide trail, in which plasma NGAL was measured in 186 
patients with acute heart failure at discharge, plasma NGAL 
was an even better prognostic indicator compared with BNP.24
Plasma NGAL in Non-CKD Patients
This study shows that plasma NGAL predicts mortality in 
patients with heart failure, even in non-CKD patients. Taking 
into consideration that creatinine is a marker of kidney func-
tion and NGAL is a marker of kidney injury, there are several 
arguments why tubular damage in patients with heart failure is 
associated with prognosis, whereas glomerular function in the 
mild impaired renal function ranges is not.
First, in patients with heart failure, decreased perfusion 
may be a key deleterious factor for the kidneys. Because the 
tubulus is more vulnerable to hypoxic damage,4–12 it is possi-
ble that small declines in renal function result in tubular dam-
age where the renal cortex stays intact, maintaining GFR.4,31 
Therefore, tubular damage might better reflect a decreased 
perfusion than eGFR.30
Second, in the acute setting, tubular markers are increased, 
whereas creatinine is still normal.14–17 A possible mechanism is 
that decreased renal perfusion in heart failure leads to compen-
satory glomerular hyperfiltration.32 In fact, renal blood flow can 
decrease by 30% to 40% without apparently affecting functional 
GFR.31 Notably, tubular markers reflect renal injury, instead of 
renal function. Tubular markers, such as plasma NGAL, are 
therefore likely to be more sensitive than creatinine.
Third, creatinine levels are dependent of muscle metabo-
lism, weight, age, and sex. Although formulas partly over-
come this limitation, creatinine is still actively secreted by the 
proximal tubule, especially when GFR is low, making creati-
nine less useful in extremes of true GFR.
Plasma NGAL Compared With eGFR  
and Cystatin C
We show that plasma NGAL is a more powerful predictor 
of mortality than eGFR. The results of the incremental value 
of plasma NGAL over eGFR are almost similar when com-
pared with the results of a more sensitive glomerular marker 
cystatin C.33,34 Although eGFR is regularly used in daily prac-
tice, cystatin C can be seen as a more accurate reflection of 
glomerular function. In acute settings, creatinine is known 
to be a slower marker.33,34 Creatinine-based formulas are less 
accurate in extremes of true eGFR,27 and this is one of the 
factors why cystatin C is superior to creatinine.35–38 More-
over, cystatin C is less dependent on body mass, decreased 
muscle mass, and cachexia, which are present in patients with 
chronic heart failure.39–42
Nevertheless, even when related to and adjusted for cystatin 
C, plasma NGAL remained to have a better prognostic value. 
This might indicate that in patients with heart failure, tubular 
damage might better reflect an impaired hemodynamic status 
as compared with glomerular function.
Limitations
Recognizing the importance of renal biomarkers in heart 
failure for improving risk stratification, there are several con-
cerns in analyzing different biomarkers. It would be best to 
approach the accuracy of risk prediction with a  multi-marker 
approach.43,44
Primary renal disease was not excluded at baseline in this 
study. Therefore, the observed relationships could have been 
affected by underlying renal disease, where associations 
among tubular damage, glomerular function, and outcome can 
be different. Larger studies are required to confirm our results, 
preferably with a specific intervention to investigate effects 
rather than associations. Also, we do not have information on 
cause of death.
Kidney disease is not only identified by low GFR and tubu-
lar damage. Unfortunately, we do not have sufficient data on 
albuminuria in the COACH cohort.
We assessed plasma NGAL, rather than urinary NGAL, 
which may be more affected by specific confounders, such as 
bacterial infection, presence of cancer or chronic obstructive 
pulmonary disease, and inflammation,30 although C-reactive 
protein was not correlated with plasma NGAL in the pres-
ent study. Plasma levels of NGAL still increase markedly 
 (≤16-fold) in the setting of renal tubular injury. Plasma NGAL 
also has the advantage of easy collection because plasma is 
already collected in the clinical setting.30
Conclusions
The present study shows the incremental prognostic value 
of plasma NGAL in patients with heart failure with and 
without renal dysfunction. Moreover, plasma NGAL is a 
stronger predictor for mortality than frequently used bio-
markers of CKD.
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CLINICAL PERSPECTIVE
Moderate to severe chronic kidney disease, mainly expressed by estimated glomerular filtration rate <60 mL/min per 1.73 m2, 
is strongly associated with increased mortality among patients with heart failure, whereas these findings are far less estab-
lished in the presence of mild impaired renal function. In different pathogenesis of kidney failure, tubulointerstitial hypoxia 
seems to be an early marker for the development of kidney failure. Several studies showed that tubular markers are increased 
before an increase of creatinine is observed. Neutrophil gelatinase–associated lipocalin (NGAL) reflects renal tubulointersti-
tial damage. Neutrophil gelatinase–associated lipocalin is an established renal marker in patients with intrinsic kidney failure 
along with other tubular markers. The novelty of this article is related to the predictive value of neutrophil gelatinase–asso-
ciated lipocalin for mortality in patients with a normal renal function. Moreover, plasma neutrophil gelatinase–associated 
lipocalin was a stronger predictor for mortality than the established renal function indices estimated glomerular filtration 
rate and cystatin C.
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Age (years) 71 ± 12 71 ± 11 0.455
Gender (% female) 37 38 0.693
LVEF (%) 34 ± 15 32 ± 14 0.174
NYHA (%) 0.012
   2 56 47
   3 41 50
   4 3 4
Systolic BP (mmHg) 119 ± 21 118 ± 21 0.733
Diastolic BP (mmHg) 68 ± 12 69 ± 12 0.311
Heart rate (bpm) 75 ± 14 74 ± 13 0.325
Medical history (%)
Hypertension 44 42 0.687
Peripheral arterial disease 17 16 0.826
Myocardial infartion 45 41 0.226
Atrial fibrillation 42 46 0.155
Stroke 17 15 0.483
COPD 24 28 0.093
Laboratory
Cystatin C (mg/l) NA 11.2 ( 7.7 - 16.2 ) -
Creatinine (µmol/l)* 110 ( 90 - 141 ) 115 ( 91 - 145 ) 0.063
Hemoglobin (g/dl) 13.1 ± 1.9 13.2 ± 2 0.862
BNP (pg/ml) 1340 ( 738 - 2144 ) 1409 ( 810 - 2144 ) 0.91
CRP (mg/l) NA 2.3 ( 0.9 - 5.1 ) -
Medication use (%)
ACE inhibitor 73 72 0.807
Angiotensin receptor bl 13 11 0.324
Beta blocker 65 67 0.588
Diuretic 96 96 0.666
Statin 37 39 0.53
Calcium antagonist 18 14 0.058
* for mg/dL divide by 88.4. Abbreviations: ACE: Angiotensin Converting Enzyme; BNP: Brain-type Natriuretic 
Peptide; Bpm: beats per minute; COPD: Chronic Obstructive Pulmonary Disease; CRP: C-Reactive Protein; 
eGFR: estimated Glomerular Filtration Rate; LVEF: Left Ventricular Ejection Fraction; NGAL: Neutrophil 
Gelatinase Associated Lipocalin; NYHA: New York Heart Association functional class.
